All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-09-09T11:04:24.000Z

Should MRD negativity post remission impact treatment decisions in ELN-intermediate risk AML?

Sep 9, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute myeloid leukemia.

During a meeting of the AML Hub Steering Committee, held on May 8, 2024, Jeffrey Lancet chaired a discussion on the question: In European LeukemiaNet (ELN) intermediate risk acute myeloid leukemia (AML), can or should measurable residual disease (MRD) assessment at the end of the treatment supersede baseline molecular risk stratification for determining next steps in treatment, for example, allogeneic bone marrow transplantation? The discussion featured Gail Roboz, Jordi Esteve, Jorge Sierra, and Roland Walter.

Lancet opens the discussion on whether MRD negativity post remission could replace transplantation in non-favorable risk AML settings. With advancements in the treatment landscape, cost concerns, and transplant-related comorbidities, such as graft-vs-host syndrome, some steering committee members supported sparing/delaying transplants for patients achieving MRD-negative remission, particularly after the first cycle of therapy. However, most opposed skipping transplants in intermediate-risk patients, except for specific genetic profiles. Concerns about the sensitivity of MRD measurement tools, especially flow cytometry, were also discussed. The lack of consensus highlights the need for more data and randomized trials. 

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
7 votes - 37 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox